CS DIAGNOSTICS Business Summary

CS Diagnostics Corp. (CSDX) is a medical technology and hygiene solutions provider that operates a dual-focus business model centered on infection control and oncology. The company generates revenue through a multi-channel distribution strategy encompassing B2B sales to hospitals, clinics, and ministries of health, alongside B2C retail and e-commerce channels. Its primary business segments include the MEDUSA Smart Disinfectant Product (SDP) platform, which provides antimicrobial hygiene solutions like wet wipes and liquid formulations, and the CS-Protect Hydrogel, an injectable tissue spacer designed to protect healthy organs during prostate cancer radiotherapy. CSDX competes directly with firms such as Cosmos Health Inc., BioScience Health Innovations, and Wellgistics Health, positioning itself as an emerging micro-cap player transitioning from development-stage operations to a global commercial rollout across the GCC, Europe, and the United States. The company is led by founder Thomas Fahrhoefer, who serves as Chairman and Chief Executive Officer, bringing over 25 years of pharmaceutical experience from major firms like Pfizer and various international medical wholesalers. The executive leadership team includes Mohammad EsSayed, Vice President and Group Chief Financial Officer, and Thomas J. Migotsch, Vice President and Chief Operating Officer, both of whom were instrumental in the company's 2024 board restructuring aimed at enhancing financial transparency and global expansion. Notable institutional backing includes major shareholdings by CS Interpharm LLC and CS Diagnostics Pharma GmbH, as well as strategic funding from San Art Capital SAS. The board is further supported by independent directors such as Prof. Dr. Ralf Herwig and Dr. Lauren Ugur, providing clinical and academic oversight as the company pursues critical FDA and EPA regulatory milestones.